• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.3478 +0.0019 (+0.55%)
Streaming Delayed Price Updated: 9:55 AM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 238,765
Open 0.3567
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3459
Today's Range 0.3451 - 0.3569
52wk Range 0.2050 - 0.3999
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CytoDyn to Present at the LD Micro Invitational XVI
May 15, 2026
From CytoDyn Inc.
Via GlobeNewswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
Via Investor Brand Network

Performance

YTD
+28.8%
+28.8%
1 Month
-2.8%
-2.8%
3 Month
+43.1%
+43.1%
6 Month
+20.8%
+20.8%
1 Year
-9.9%
-9.9%

More News

Read More
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
May 11, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
April 27, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
From BioMedWire
Via GlobeNewswire
News headline image
CytoDyn to Host Investor Webcast
April 23, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
April 22, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
April 21, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
April 20, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present at the AACR Annual Meeting 2026
April 14, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
March 24, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
March 05, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
February 20, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
January 27, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
December 2025 Letter to Shareholders
December 16, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
December 08, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces Resolution of Class Action Lawsuit
December 01, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
November 24, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
November 03, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
October 22, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
October 09, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
September 2025 Letter to Shareholders
September 30, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
September 25, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
September 16, 2025
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
September 04, 2025
From CytoDyn Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cytodyn Inc publicly traded?
Yes, Cytodyn Inc is publicly traded.
What exchange does Cytodyn Inc trade on?
Cytodyn Inc trades on the OTC Traded
What is the ticker symbol for Cytodyn Inc?
The ticker symbol for Cytodyn Inc is CYDY on the OTC Traded
What is the current price of Cytodyn Inc?
The current price of Cytodyn Inc is 0.3478
When was Cytodyn Inc last traded?
The last trade of Cytodyn Inc was at 05/20/26 09:55 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap